Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
Production / Operations Routine +

High Tide Reports Record Quarterly Distribution of 7.6 Tonnes of Medical Cannabis Through Remexian Pharma GmbH, Accelerating German Market Leadership

High Tide Germany Distribution Surges as Bank Financing Validates Liquidity

By The Northwire Desk — AI Analysis May 06, 2026 · 06:00 HITI · 3.22 High Tide Inc.
Executive Summary
  • Operational Update: High Tide's German subsidiary, Remexian Pharma GmbH, distributed a record 7.6 tonnes of medical cannabis in the second fiscal quarter ended April 30, 2026.
  • Growth Metrics: This volume represents a 21% sequential increase and a 49% year-over-year increase compared to the prior year period.
  • Ownership Structure: High Tide holds a 51% ownership stake in Remexian Pharma GmbH, acquired for €26.4 million (~C$38 million) in late 2025.
  • Market Context: Germany imported 201.1 tonnes of medical cannabis in 2025; High Tide aims to capture a larger share of the Canadian-sourced portion (approx. 93 tonnes).
  • Financial Reporting: Tonnage figures are preliminary and unaudited. Full financial results for Q2 FY2026 (revenue, EBITDA) are expected in June 2026.
  • Management Commentary: CEO Raj Grover cites the growth as evidence of a scalable distribution model leveraging High Tide's procurement capabilities from $2.2 billion in Canadian sales history.
Material Impact
  • Validation of Strategy: The record tonnage confirms the scaling narrative established in Q1 FY2026 earnings (March 17), where Remexian revenue grew to $25M for two months in Q4 and continued into Q1. It validates the "repeatable, capital-efficient distribution engine" claim made by management.
  • Financing Context: This operational update follows immediately after the May 5 announcement of a $40 million credit facility with a Big 5 Canadian bank. The volume growth provides confidence that the new senior debt will be serviced by operating cash flow rather than equity dilution, reinforcing the institutional validation mentioned in the financing news.
  • Earnings Expectations: While positive, this is an operational metric (tonnage) rather than financial results (revenue/EBITDA). The transcript notes import permit delays in Portugal and Germany have constrained margins previously; investors will wait for June financials to see if volume translates to improved gross margins (target 20-25%).
  • Market Reaction: Given the Q1 earnings beat and financing news, this update is largely expected by the market. It serves as a confirmation rather than a surprise catalyst. The lack of immediate financial data limits the materiality compared to the financing announcement itself.
HITI · Price
Company Overview
  • Company: High Tide Inc. is a Canadian cannabis company operating retail stores under the Canna Cabana brand and distribution operations via Remexian Pharma GmbH in Germany.
  • Flagship Project: The dual-engine model consists of:
    1. Canna Cabana Retail: 220+ locations across Canada with over 2.58 million loyalty members (Cabana Club). Focus on white-label SKUs and ELITE membership growth.
    2. Remexian Pharma GmbH: Majority-owned German medical cannabis distributor. Acquired in late 2025 to enter the European market, leveraging Canadian biomass supply chains.
  • Development Status: Retail segment is mature with positive free cash flow. International segment (Germany) is in growth phase with accelerating volume but facing regulatory delays on import permits affecting margins.
Read the original news release →

More from High Tide Inc.

Jun 17, 2026 · 06:00

Remexian distribution partnerships reinforce German growth thesis, but stock has already priced in the catalyst.

M&A / Property Jun 15, 2026 · 16:00

First net income and record EBITDA beat expectations, but same-store sales decline and flat price action suggest skepticism remains.

Earnings Jun 15, 2026 · 15:31

High Tide receives approval for $40M of facilities

Financings Jun 15, 2026 · 06:00

High Tide to Acquire Northern Helm, Adding Four Established Retail Cannabis Stores in Ontario

M&A / Property Jun 10, 2026 · 11:00

Routine store expansion in line with guidance; market remains skeptical as stock drifts lower post-Q1 beat.

Production / Operations May 11, 2026 · 06:00

Insider buying and surging German medical cannabis market share signal conviction as High Tide shores up a Big Five bank credit line.

Production / Operations